Basic Information
| LncRNA/CircRNA Name | LINC01225 |
| Synonyms | LINC01225, LOC149086 |
| Region | GRCh38_1:31500085-31509648 |
| Ensemble | ENSG00000260386 |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | Drug | |||
| Variant | Cell Growth | Circulating | |||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | hepatocellular carcinoma |
| ICD-0-3 | C22.0 |
| Methods | Microarray, qPCR, Western blot, RIP, Flow cytometry assay etc. |
| Sample | HCC tissues, cell lines (SMCC7721, MHCC97H, L02) |
| Expression Pattern | up-regulated |
| Function Description | Here, we verified that LINC01225 was upregulated in HCC. Knockdown of LINC01225 resulted in inhibited cell proliferation and invasion with activated apoptosis and cell cycle arrest in vitro. Overexpression of LINC01225 in LINC01225 knockdown cells presented that attenuated cell proliferation and invasion were restored and enhanced. Subcutaneous and tail vein/intraperitoneal injection xenotransplantation model in vivo validated reduced tumor progression and metastasis. Investigation of mechanism found that LINC01225 could bind to epidermal growth factor receptor (EGFR) and increase the protein level of EGFR, and subsequently fine tune the EGFR/Ras/Raf-1/MEK/MAPK signaling pathway. |
| Pubmed ID | 26938303 |
| Year | 2016 |
| Title | LINC01225 promotes occurrence and metastasis of hepatocellular carcinoma in an epidermal growth factor receptor-dependent pathway. |
External Links
| Links for LINC01225 | GenBank HGNC NONCODE |
| Links for hepatocellular carcinoma | OMIM COSMIC |